Scarica l'app Stockscreener
61.31
1.21%
0.73
Dopo l'orario di chiusura:
61.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$60.58
Aprire:
$60.53
Volume 24 ore:
2.33M
Relative Volume:
0.68
Capitalizzazione di mercato:
$27.30B
Reddito:
$2.44B
Utile/perdita netta:
$1.36B
Rapporto P/E:
32.11
EPS:
1.9093
Flusso di cassa netto:
$574.14M
1 W Prestazione:
+4.62%
1M Prestazione:
+4.95%
6M Prestazione:
+35.88%
1 anno Prestazione:
+68.85%
Intervallo 1D:
$60.37
$61.60
Intervallo di 1 settimana:
$58.18
$62.13
Portata 52W:
$34.08
$62.13
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
61.31 | 26.97B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | UBS | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
RPHC5824520 Bond Profile — Key Metrics - TradingView
30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc. - MarketBeat
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity - Kalkine Media
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma stock hits all-time high at 60.44 USD - Investing.com
Royalty Pharma stock hits all-time high at 60.44 USD By Investing.com - Investing.com Nigeria
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Commerzbank Aktiengesellschaft FI Invests $1.20 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma - simplywall.st
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale - Stock Titan
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares - Investing.com South Africa
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated - Stock Titan
Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan - Stock Titan
LYNWOOD PRICE CAPITAL MANAGEMENT LP's Royalty Pharma PLC(RPRX) Holding History - GuruFocus
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 10.49% Potential Upside - DirectorsTalk Interviews
S&CO Inc. Buys Shares of 358,302 Royalty Pharma PLC $RPRX - MarketBeat
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years - Benzinga
Royalty Pharma (RPRX) Following Mixed Earnings Still Looks Close To Fair Value - Sahm
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? - Yahoo Finance
Royalty Pharma (RPRX) holder TPC RP EPA1 LLC eyes 11,002-share stock sale - Stock Titan
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug - Benzinga
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout Setup - ChartMill
Royalty Pharma (RPRX) files to potentially sell 11.9M Class A shares - Stock Titan
RPRX (RPRX) investor files to sell 125,000 Class A shares on NASDAQ - Stock Titan
Zealand gains $100M in funding from Royalty Pharma (RPRX:NASDAQ) - Seeking Alpha
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million - The Manila Times
Zealand Pharma sells rusfertide royalty rights for $100 million - Investing.com
Zealand Pharma sells rusfertide royalty rights for $100 million By Investing.com - Investing.com UK
Behavioral Patterns of RPRX and Institutional Flows - Stock Traders Daily
Royalty Pharma plc and Zealand Pharma A/S Enter into Rusfertide Funding Agreement for $100 Million - marketscreener.com
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide - The Manila Times
Royalty Pharma PLC (NASDAQ:RPRX) Plans Quarterly Dividend of $0.23 - MarketBeat
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript - AOL.com
Royalty Pharma PLC $RPRX Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Royalty Pharma PLC $RPRX Stake Boosted by Handelsbanken Fonder AB - MarketBeat
A potential blood-disorder therapy is at the center of a $100M deal - Stock Titan
How Royalty Pharma’s Stronger H1 2026 Earnings and New Academic Focus At Royalty Pharma (RPRX) Has Changed Its Investment Story - webull.com
Should Income Investors Look At Royalty Pharma plc (NASDAQ:RPRX) Before Its Ex-Dividend? - webull.com
Royalty Pharma publishes transcript of Q2 2026 financial results call - Bitget
A3LZUK Bond Profile — Key Metrics - TradingView
A3LZUK Bond Coupon Profile — Rate & Payments - TradingView
Royal Bank of Canada Purchases 23,479 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824520 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Royalty Pharma (RPRX) CEO gets share award and gifts partnership interests - Stock Titan
Royalty Pharma plc (RPRX) CFO logs equity award and 18,500-share gift - Stock Titan
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):